TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Regulation FD DisclosureItem 7.01
Tonix Pharmaceuticals Holding Corp. (the “Company”) intends to use an updated investor presentation to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain non-public information.A copy of the presentation is filed as Exhibit 99.01.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01, is furnished to, and shall not be deemed to be “filed” for the purposes of, Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.The information contained in Item 7.01 of this Current Report shall not be incorporated by reference into any registration statement or any other document filed to the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing.By filing this Current Report on Form 8-K and furnishing the information contained in this Item 7.01, including Exhibit 99.01, the Company makes no admission as to the materiality of any such information that it is furnishing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| 99.01 | Corporate Presentation by the Company for July 2017* |
* Furnished herewith.
Tonix Pharmaceuticals Holding Corp. ExhibitEX-99.1 2 s106760_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 © 2017 Tonix Pharmaceuticals Holding Corp. July 2017 Version P0072 7 – 6 – 17 Investor Presentation © 2017 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward – Looking Statements Certain statements in this presentation regarding strategic plans,…To view the full exhibit click here
